Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rademikibart (CBP-201) Monotherapy in Moderate-to-Severe Atopic Dermatitis
NCT05614817Phase 3Withdrawn
- Sponsor
- Connect Biopharma
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of rademikibart in atopic dermatitis (AD) (6 arms), sponsored by Connect Biopharma. Primary endpoints: Investigator Global Assessment Response (0-1) at 16 weeks and Eczema Area and Severity Index 75% Improvement at 16 weeks. Planned start Dec 2022; status: withdrawn.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05614817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614817.